Interdisciplinary Metabolic Medicine Trials Unit, Medical University of Graz, Graz, Austria.
Division of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Diabetes Care. 2023 Feb 1;46(2):463-468. doi: 10.2337/dc22-1622.
To investigate the safety and feasibility of 3 nonconsecutive days of intermittent fasting (IF) per week over 12 weeks in participants with insulin-treated type 2 diabetes.
Forty-six people were randomized to an IF or control group. Dietary counseling and continuous glucose monitoring was provided. Coprimary end points were the change in HbA1c from baseline to 12 weeks and a composite end point (weight reduction ≥2%, insulin dose reduction ≥10%, and HbA1c reduction ≥3 mmol/mol).
The IF group showed a significant HbA1c reduction (-7.3 ± 12.0 mmol/mol) compared with the control group (0.1 ± 6.1 mmol/mol) over 12 weeks (P = 0.012). The coprimary end point was achieved by 8 people in the IF and none in the control group (P < 0.001). No severe hypoglycemia occurred.
IF is a safe and feasible dietary option to ameliorate glycemic control while reducing total daily insulin dose and body weight in insulin-treated people with type 2 diabetes.
探究每周进行 3 天非连续间歇性禁食（IF）、持续 12 周对接受胰岛素治疗的 2 型糖尿病患者的安全性和可行性。
46 名参与者被随机分配至 IF 组或对照组。提供饮食咨询和连续血糖监测。主要复合终点为 12 周时与基线相比 HbA1c 的变化和复合终点（体重减轻≥2%、胰岛素剂量减少≥10%、HbA1c 降低≥3 mmol/mol）。
IF 组与对照组相比，12 周时 HbA1c 显著降低（-7.3 ± 12.0 mmol/mol 比 0.1 ± 6.1 mmol/mol；P = 0.012）。IF 组有 8 人达到主要复合终点，而对照组无人达到（P < 0.001）。未发生严重低血糖。
IF 是一种安全且可行的饮食选择，可改善血糖控制，同时减少接受胰岛素治疗的 2 型糖尿病患者的每日总胰岛素剂量和体重。
